DPx Holdings Sells Fine Chemicals Business
PTSM: Pharmaceutical Technology Sourcing and Management
Investment group Ardian will acquire the fine chemicals business activities of DPx Holdings B.V.
Ardian, a private investment company, together with current management, announced on July 22 the acquisition of the Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) business activities of DPx Holdings B.V., based in Linz, Austria. Details of the transaction were not disclosed.
ES develops and produces chemical intermediate products for agriculture and other industries. IM produces maleic anhydride, intermediates, derivatives, and esters. The groups had a combined sales of €200 million for the 2014 financial year and 390 employees.
With the support of Ardian, the management of ES and IM plans to significantly strengthen its market position, the company reports in a statement. Investment will focus on expanding the product portfolio through organic growth, strategic acquisitions, and expanding into new markets.
DPx Holdings B.V. is the parent company of the Patheon, DPx Fine Chemicals, and Banner Life Sciences businesses.
Source: DPx Holdings B.V.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
